In a surprise move, the Food and Drug Administration has set separate dates for advisory panels to review two different drugs for Duchenne muscular dystrophy, a rare genetic disorder that leaves young boys wheelchair bound. Most people expected the agency to hold back-to-back meetings next month.
Instead, one panel meeting will be held on Nov. 24 to review a drug from BioMarin Pharmaceutical, while a Sarepta Therapeutics medicine will be scrutinized on Jan. 22, 2016. Normally, such doings do not generate much notice, especially for rare disease drugs. But the Duchenne drugs have been the focus of intense interest over the past few years thanks to a combination of unusual circumstances.
No Comment